** Shares of drugmaker Y-mAbs Therapeutics fall 6.6% to $6.90

** YMAB says it is creating two business units, one to accelerate the clinical development of its radiopharmaceuticals unit and another to optimize the commercial growth of Danyelza

** Company's radiopharmaceuticals unit develops targeted cancer therapies by delivering high doses of radiation directly to tumors while minimizing exposure to healthy tissues

** Danyelza is an FDA-approved cancer therapy for the treatment of relapsed or refractory neuroblastoma in the bone or bone marrow

** YMAB also plans to lay off 13% of its employees, depending on whether a portion of the impacted employees accepts newly created positions

** Company had 100 full-time employees as of Dec. 31, 2023 - SEC filing

** YMAB says it plans to move some roles from Denmark to the U.S.

** YMAB gained ~14% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))